Onco-Innovations Ltd
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$84.6M
Onco-Innovations Ltd. is a Canadian biotech company, which engages in cancer research and treatment, specializing in oncology. The company is headquartered in Calgary, Alberta. The company went IPO on 2024-11-27. Its product candidate is ONC010, which is an inhibitor of the deoxyribonucleic acid (DNA) repair enzyme Polynucleotide Kinase 3'-Phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. ONC010 has undergone in-vitro and in-vivo testing in human cancer cells and mice, respectively, and has the ability to increase the effectiveness of cancer treatments, as well as induce synthetic lethality in phosphatase and tensin homologue (PTEN)-deficient cells. Its research and development roadmap covers manufacturing, discovery, pre-clinical testing, and clinical translation activities. The Clinical Translation program includes Phase I to Phase III clinical trials. Through its SynoGraph artificial intelligence platform, it enhances precision oncology by accelerating patient identification, optimizing treatment planning, and streamlining drug development across its pipeline.
Onco-Innovations Ltd. is a Canadian biotech company, which engages in cancer research and treatment, specializing in oncology. The company is headquartered in Calgary, Alberta. The company went IPO on 2024-11-27. Its product candidate is ONC010, which is an inhibitor of the deoxyribonucleic acid (DNA) repair enzyme Polynucleotide Kinase 3'-Phosphatase (PNKP) in a nanoparticle formulation based on drug delivery technology. ONC010 has undergone in-vitro and in-vivo testing in human cancer cells and mice, respectively, and has the ability to increase the effectiveness of cancer treatments, as well as induce synthetic lethality in phosphatase and tensin homologue (PTEN)-deficient cells. Its research and development roadmap covers manufacturing, discovery, pre-clinical testing, and clinical translation activities. The Clinical Translation program includes Phase I to Phase III clinical trials. Through its SynoGraph artificial intelligence platform, it enhances precision oncology by accelerating patient identification, optimizing treatment planning, and streamlining drug development across its pipeline.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.